The FDA has awarded US approval to Pfenex’s drug PF708, it has emerged, as a treatment for osteoporosis in certain patients at high risk for fracture, just like its reference product, Eli Lilly’s Forteo (teriparatide injection).
Submitted for approval last December, supporting data illustrated that PF708 showed comparable efficacy to Lilly’s drug in terms of the anti-drug antibody incidence and bone mineral density after 24 weeks of treatment.
